Cardiol Therapeutics Inc Class A
$ 1.07
1.90%
11 Jun - close price
- Market Cap 119,307,000 USD
- Current Price $ 1.07
- High / Low $ 1.07 / 1.02
- Stock P/E N/A
- Book Value 0.16
- EPS -0.28
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.78 %
- ROE -1.74 %
- 52 Week High 1.71
- 52 Week Low 0.88
About
Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.
Analyst Target Price
$7.22
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-30 | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-14 | 2024-08-12 | 2024-05-14 | 2024-03-26 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -0.0516 | -0.07 | -0.0857 | -0.0722 | -0.1 | -0.09 | -0.18 | -0.1 | -0.12 | -0.09 | -0.09 | -0.12 |
| Estimated EPS | -0.0826 | -0.11 | -0.0775 | -0.0997 | -0.08 | -0.1167 | -0.08 | -0.13 | -0.12 | -0.09 | -0.12 | -0.12 |
| Surprise | 0.031 | 0.04 | -0.0082 | 0.0275 | -0.02 | 0.0267 | -0.1 | 0.03 | 0 | 0 | 0.03 | 0 |
| Surprise Percentage | 37.5303% | 36.3636% | -10.5806% | 27.5827% | -25% | 22.8792% | -125% | 23.0769% | 0% | 0% | 25% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRDL
2026-05-15 20:39:16
MMCAP International Inc. SPC and MM Asset Management Inc. have filed an amended passive investment disclosure (SCHEDULE 13G/A) for Cardiol Therapeutics Inc., reporting shared beneficial ownership of 21,063,856 Class A Common Shares, which represents 17.9% of the class as of March 31, 2026. This total includes 15,352,317 directly owned shares and an additional 5,711,539 shares underlying warrants exercisable within 60 days. The filing clarifies that the Fund is the direct owner and the Adviser serves as the investment manager, with each disclaiming ownership beyond explicitly stated shares.
2026-05-15 04:39:44
This article provides news headlines related to Cardiol Therapeutics Inc. (Nasdaq: CRDL). Key updates include the FDA approving Cardiol's Investigational New Drug application for CardiolRx to test an oral cannabidiol formulation in acute myocarditis patients, and the company's stock movements in August 2021.
2026-05-15 02:39:16
This page provides a collection of recent news headlines, press releases, and research articles related to Cardiol Therapeutics Inc. (CRDL). The news covers financial updates, clinical study results, analyst ratings, stock performance, and company announcements. Key topics include their CBD-based drug for pericarditis, financial offerings, and earnings reports, demonstrating ongoing developments and market reactions for the company.
2026-05-14 17:09:29
This page provides news and updates for Cardiol Therapeutics Inc. (CRDL), a company focused on developing therapies for inflammatory heart diseases. Recent highlights include positive topline data from its Phase II MAvERIC-Pilot study for recurrent pericarditis, the company meeting and beating EPS estimates, and gaining Orphan Drug Designation for its lead candidate. The news also covers advancements in their trials and studies using cannabidiol for cardioprotective effects.
2026-05-14 16:10:17
This article provides a list of recent news headlines concerning Cardiol Therapeutics Inc. (CRDL), including financial performance updates, clinical study results for their CBD-based drugs, analyst coverage, and stock movement news. The company is actively involved in developing therapies for inflammatory heart diseases and has seen various market reactions to its announcements of public offerings and clinical trial progress.
2026-05-14 00:39:08
Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ on May 19, 2026. The late-stage life sciences company is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead candidate CardiolRx™ and a novel formulation CRD-38. A live webcast and replay of the event will be available on the company's investor relations website.
